Short term outcome following acute phase switch among P2Y₁₂ inhibitors in patients presenting with acute coronary syndrome treated with PCI: A systematic review and meta-analysis including 22,500 patients from 14 studies.

ABSTRACT:

Introduction

The efficacy and safety of switching P2Y₁₂ receptor antagonists in patients admitted for acute coronary syndrome (ACS) remain unclear. We assessed the short-term clinical outcomes (in-hospital and within 30 days) of switching P2Y₁₂ inhibitor (P2Y₁₂I) drugs versus maintaining the same regimen by performing a comprehensive review and meta-analysis of available data.

Methods

MEDLINE/PubMed/SCOPUS/Cochrane databases were screened for studies regarding switching of P2Y₁₂I in patients with ACS that reported 30 days follow-up. Major cardiac events (MACE) and bleeding were compared between patients who were switched/not switched.

Results

22,500 patients from 14 studies were included. Unstable angina/non-ST elevation myo

SUBMITTER: Cerrato E 

PROVIDER: S-EPMC6288462 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature